Title for MeetingAbstracts
Alphabetical listing of titles
Zidovudine and interferon-alpha versus zidovudine in patients with persistent p24 antigenemia.
Zidovudine and interferon-alpha versus zidovudine in symptomatic HIV-1 infection (CD4+ count greater than or equal to 150 x 10(6)/l). The National AIDS Treatment Evaluation Centre, (NATEC).
Zidovudine and interferon-alpha versus zidovudine in symptomatic HIV-infection (CD4+ count greater than or equal to 150/mm(3)): 24 weeks follow-up.
Zidovudine and interleukin-2 in WR2 HIV infected patients: evidence for stimulated immunologic reactivity against HIV.
Zidovudine and lamivudine (ZDV/3TC) seminal plasma:blood plasma (SP:BP) concentration ratios do not predict total SP exposure.
Zidovudine and slowing of progression to AIDS: the unnatural history of disease.
Zidovudine as a possible treatment for thrombocytopenia associated with AIDS and ARC.
Zidovudine as a treatment of hepatitis C in HIV infected patients.
Zidovudine associated resistance mutations among zidovudine treated Thai adults infected with HIV-1 subtype E.
Zidovudine delays development of AIDS for patients with 4c-2, 3 and 4a HIV disease.
Zidovudine does not antagonize fansidar in preventing toxoplasma encephalitis in HIV infected patients.
Zidovudine effect on lysozyme activity and release in human granulocytes.
Zidovudine effect on vitamin B12 and folate measured by the deoxyuridine suppression test in HIV patients.
Zidovudine genotypic resistance in HIV-1 infected newborns in the French HIV-1 perinatal cohort study.
Zidovudine in a low-dose schedule in infected children: a Brazilian experience.
Zidovudine in ARC and AIDS patients: clinical, immunological and virological efficacy.
Zidovudine in association with anti-CD4 monoclonal antibody in the treatment of HIV infection.
Zidovudine in early asymptomatic HIV disease: a controlled trial in subjects with greater than 500 CD4+ cells/microL. ACTG 019 Team. AIDS Clinical Trials Group.
Zidovudine induced mutations in chronically treated Mexican children with AIDS.
Zidovudine induces remission of chronic active hepatitis C in HIV-1 carriers.
Zidovudine levels in AIDS and ARC: virologic and haematologic effects.
Zidovudine myopathy--a prospective study.
Zidovudine Myopathy.
Zidovudine or zidovudine/acyclovir in patients with asymptomatic HIV infection and CD4+ cell counts greater than 400/microL.
Zidovudine pharmacokinetics and intracellular pharmacology of zidovudine in HIV-infected women and newborn infants.
Zidovudine pharmacokinetics in asymptomatic HIV-positive women.
Zidovudine pharmacokinetics in children following I.V. and/or oral route.
Zidovudine pharmacokinetics in premature infants exposed to HIV. American Pediatric Association and Society for Pediatric Research annual meeting; 1996 May 6-10; Washington, D.C.
Zidovudine plus alpha interferon 2b: a controlled study on 150 asymptomatic IVDA.
Zidovudine plus zalcitabine combination therapy versus NAIV children with HIV/AIDS in Romania.